Back to results
US 2021/0060150 A1Published application
Novel adenovirus
AssigneeGlaxosmithkline Biologicals SA
InventorsStefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra VITELLI, Alfredo NICOSIA, Riccardo CORTESE
Life of this patent
Estimating the term…
Abstract
There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.
Claims21
1-95. (canceled)
An immunogenic composition for generating a T cell response in a subject, the immunogenic composition comprising:
- a first composition to be administered to the subject including a recombinant adenovirus comprising a polynucleotide comprising:
- (a) a first polynucleotide which encodes a polypeptide having the amino acid sequence according to SEQ ID NO:
- 1,
- (b) a second polynucleotide which encodes a polypeptide having the amino acid sequence according to SEQ ID NO:
- 5,
- (c) a third polynucleotide which encodes a polypeptide having the amino acid sequence according to SEQ ID NO:
- 3, and
- (d) a fourth polynucleotide which encodes a mycobacterial Rv1196 antigen consisting of the amino acid sequence of SEQ ID NO:68, wherein the fourth polynucleotide is operatively linked to one or more sequences which direct expression of said mycobacterial Rv1196 antigen in a host cell.
5 more elements
Dependencies are inferred from the claim text.